Bard PowerPort vs AngioDynamics Port Catheter – Two Separate MDLs Explained

Bard PowerPort vs AngioDynamics is one of the most common points of confusion in port catheter litigation. Both companies make implanted ports for chemotherapy and long-term infusion. Both now face thousands of claims that their catheters crack, fracture, and migrate inside the body. However, these are two separate federal MDLs. They sit in different courts, before different judges, on very different timelines. The Bard PowerPort vs AngioDynamics distinction matters because your device brand decides which case you have.

What Is the Bard PowerPort vs AngioDynamics Debate About?

An implanted port is a small reservoir placed under the skin. A thin catheter runs from that port into a large vein near the heart. Doctors use ports to deliver chemotherapy, antibiotics, and contrast dye. For example, many cancer patients keep a port for months or years.

The core allegation in the Bard PowerPort vs AngioDynamics comparison is nearly identical. Both makers used polyurethane catheters filled with barium sulfate, a material that shows up on imaging scans. Plaintiffs allege that barium sulfate particles wash out of the catheter surface over time. That leaves microscopic pits and notches. As a result, the catheter allegedly becomes brittle and prone to splitting.

Bard’s cases involve the PowerPort, PowerPort ClearVUE, SlimPort, and related devices using ChronoFlex material. Defendants include C.R. Bard, Bard Access Systems, and parent company Becton Dickinson. AngioDynamics cases involve the SmartPort, Xcela, Vortex, and BioFlo lines, plus devices from its Navilyst Medical unit. Reported injuries in both litigations overlap heavily. Typically they include catheter fracture, fragment migration, bloodstream infection, sepsis, blood clots, cardiac arrhythmia, and vein or organ perforation. Neither line has been recalled for the barium sulfate degradation issue.

MDL Case Status and Key Facts

The Bard docket is roughly nine times larger. It also runs several years ahead. Judge Campbell set a bellwether window running from spring through December 2026. The first federal trial reached a verdict in May 2026.

That result was mixed. Jurors sided with Bard and Becton Dickinson on failure to warn, failure to instruct, and consumer fraud. However, the jury deadlocked on the central design defect claim. It also hung on the unlawful trade practices count. As a result, the biggest question in the litigation remains open. Additional trials are set for August 18, October 13, and December 1, 2026, with another in February 2027.

MDL 3125 is far earlier. Each side must name nine bellwether discovery candidates by August 4, 2026. Preliminary discovery continues into 2027. In most cases, observers expect no AngioDynamics trial before 2028. You can verify current counts through the JPML pending MDL statistics and review device complaints in the FDA MAUDE adverse event database.

Who Qualifies for a Bard PowerPort vs AngioDynamics Claim?

Eligibility starts with the device itself. You generally need a port implanted from roughly 2000 onward, depending on the model. Bard began using ChronoFlex material in its catheters around 2006. AngioDynamics claims often center on devices implanted after 2010. Typically, your implant record or operative report identifies the exact brand and lot.

Qualifying injuries are similar across both MDLs. They include catheter fracture or breakage, migration of a fragment, deep vein thrombosis, pulmonary embolism, bloodstream infection, sepsis, endocarditis, vessel perforation, and heart rhythm problems. Revision or removal surgery strengthens a claim. Deaths linked to a port failure may support a wrongful death case.

Evidence matters more than the brand in the Bard PowerPort vs AngioDynamics analysis. Attorneys typically request implant and explant records, imaging studies, hospital admission notes, and product stickers or identification cards. The device itself is valuable if it was retained after removal. However, many claimants no longer have it. That is not automatically disqualifying. A licensed attorney can tell you whether your records support a claim.

How to File a Bard PowerPort vs AngioDynamics Claim

Start by gathering documents. Request complete records from the hospital or oncology center that placed the port. Ask specifically for the operative report and any device identification labels. Those pages usually reveal the manufacturer. This step effectively answers the Bard PowerPort vs AngioDynamics question for your own case.

Next, consult a licensed product liability attorney who handles MDL work. Most offer free case reviews and work on contingency. Your lawyer files directly into MDL 3081 or MDL 3125 under the applicable direct filing order. Filing in the wrong MDL wastes months.

After filing, you complete a plaintiff fact sheet. This is a detailed sworn questionnaire covering your medical history, implant dates, injuries, and treatment. Deadlines are strict in both courts. Missing one can lead to dismissal. Separately, watch your state’s statute of limitations. These deadlines commonly run one to six years and often start when you discovered the injury. The Cornell Legal Information Institute overview of statutes of limitations explains the basic framework.

Settlement Updates and What to Expect

No global settlement exists in either litigation as of July 2026. Bard has not announced a settlement program. AngioDynamics is still years from its first trial. Any figure you see promising a specific payout is speculation.

Bellwether outcomes drive negotiations. The split May 2026 verdict gave both sides something. Bard defeated the warning claims. However, the hung jury on design defect kept plaintiff leverage intact. Upcoming trials reportedly focus on fracture and thrombosis injuries rather than infection. Many analysts view those facts as stronger for plaintiffs. As a result, the August and October 2026 trials are worth watching closely.

Compensation varies widely and depends on individual facts. Factors typically include injury severity, whether surgery was required, permanent damage, medical bills, lost income, and your state’s damage caps. The Bard PowerPort vs AngioDynamics timeline gap also matters. Bard claimants may see resolution sooner simply because that MDL is more mature. You may qualify for compensation, but only a licensed attorney can assess your specific claim.

State-by-State Considerations

MDL cases apply the law of the state where the claim arose. That means tort reform rules follow you into federal court. Damage caps, comparative fault rules, and statutes of repose all vary. For example, Texas caps certain noneconomic damages and applies a strict products liability repose period. California, Florida, New York, and Pennsylvania contribute large plaintiff counts to both dockets, reflecting their cancer center populations.

Review your state’s rules before filing. See our guides for California tort reform laws, Texas tort reform laws, Florida tort reform laws, and New York tort reform laws. An attorney licensed in your state should confirm which rules apply.

Frequently Asked Questions

How do I know which manufacturer made my port?

Your operative report and implant card list the brand and model. Hospitals also keep device labels in the surgical record. Your attorney can request these records directly if you no longer have them.

Can one lawsuit cover both manufacturers?

No. The Bard PowerPort vs AngioDynamics cases are separate MDLs with separate defendants and separate judges. Each claim proceeds against the maker of the device you actually received.

Is it too late to file if my port was removed years ago?

Possibly not. Many states start the clock when you discovered the injury and its cause. However, deadlines are unforgiving, so speak with a licensed attorney promptly.

Check If You May Qualify

Mass tort eligibility depends on your specific exposure, injuries, and the state where you live. A licensed mass tort attorney can evaluate your situation at no upfront cost — most work on contingency, meaning you pay nothing unless you recover compensation.

Official Sources & Resources

For verified mass tort and MDL information:

• JPML: jpml.uscourts.gov — official MDL statistics and transfer orders
• DOJ: justice.gov — settlement announcements and press releases
• FDA: fda.gov — drug recalls, warning letters, and safety alerts
• CDC: cdc.gov — health condition data and exposure guidelines
• EPA: epa.gov — environmental contamination data
• Cornell LII: law.cornell.edu — plain-English legal definitions

Content last reviewed July 2026. This is general educational information, not legal advice. If you notice outdated information, please contact us.

Related Guides

• All Active MDL Cases
• More in This Category
• Tort Reform by State — 50-State Comparison
• All 50 State Tort Reform Guides
• Mass Tort Explainers
• Demographic Guides
• Mass Tort Tips
• Georgia Tort Reform Guide
• North Carolina Tort Reform Guide
• Illinois Tort Reform Guide

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.